Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications

Identifier:  imarina:9004678

Handle: https://hdl.handle.net/20.500.11797/imarina9004678

Authors:  Bullon-Vela, Vanessa; Abete, Itziar; Tur, Josep A; Konieczna, Jadwiga; Romaguera, Dora; Pinto, Xavier; Corbella, Emili; Martinez-Gonzalez, Miguel A; Sayon-Orea, Carmen; Toledo, Estefania; Corella, Dolores; Macias-Gonzalez, Manuel; Tinahones, Francisco J; Fito, Montserrat; Estruch, Ramon; Ros, Emilio; Salas-Salvado, Jordi; Daimiel, Lidia; Mascaro, Catalina M; Angeles Zulet, Maria; Alfredo Martinez, Jose

Abstract:
Background: Visceral adipose tissue (VAT) has a hazardous influence on systemic inflammation, insulin resistance and an adverse metabolic profile, which increases the risk of developing non-alcoholic fatty liver disease (NAFLD) and chronic complications of diabetes. In our study we aimed to evaluate the association of VAT and the triglyceride glucose (TyG) as a proxy of insulin resistance surrogated with metabolic and liver risk factors among subjects diagnosed with metabolic syndrome (MetS). Methods: A cross-sectional study was performed including 326 participants with MetS (55–75 years) from the PREDIMED-Plus study. Liver-status markers, VAT and TyG were assessed. Participants were stratified by tertiles according to VAT (n = 254) and TyG (n = 326). A receiver operating characteristic curve was used to analyse the efficiency of TyG for VAT. Results: Subjects with greater visceral fat depots showed worse lipid profile, higher homeostatic model assessment for insulin resistance (HOMA-IR), TyG, alanine transaminase (ALT), fibroblast growth factor-21 (FGF-21), fatty liver index (FLI) and hepatic steatosis index (HSI) compared with participants in the first tertile. The multi-adjusted linear-regression analyses indicated that individuals in the third tertile of TyG (>9.1−10.7) had a positive association with HOMA-IR [β = 3.07 (95% confidence interval (CI) 2.28−3.86; p trend < 0.001)], ALT [β = 7.43 (95% CI 2.23−12.63; p trend = 0.005)], gamma glutamyl transferase (GGT) [β = 14.12 (95% CI 3.64−24.61; p trend = 0.008)], FGF-21 [β = 190.69 (95% CI 93.13−288.25; p trend < 0.001)], FLI [β = 18.65 (95% CI 14.97−22.23; p trend < 0.001)] and HSI [β = 3.46 (95% CI, 2.23−4.68; p trend < 0.001)] versus participants from the first tertile. Interestingly, the TyG showed the largest area under the receiver operating curve (AUC) for women (AUC = 0.713; 95% CI 0.62−0.79) compared with men (AUC = 0.570; 95% CI 0.48−0.66). Conclusions: A disrupted VAT enlargement and impairment of TyG are strongly associated with liver status and cardiometabolic risk factors linked with NAFLD in individuals diagnosed with MetS. Moreover, the TyG could be used as a suitable and reliable marker estimator of VAT.